Doctor Robert Oldham | University of Southampton

Publications

8 publications

Page 1 of 1

CD40L and IL-4 suppress NK cell-mediated antibody-dependent cellular cytotoxicity through the HLA-E:NKG2A axis

Lara V. Graham, Ludmila Horehajova, Marco V. Haselager, Jack G. Fisher, Jamie Lee Roos, Russell B. Foxall, Mel John, Kerry L. Cox, Robert J. Oldham, Martin C. Taylor, Margaret Ashton-Key, Ben Sale, Laura G. Bartlett, Ali Roghanian, Eric Eldering, Andres F. Vallejo, Francesco Forconi, Salim I. Khakoo, Mark S. Cragg & Matthew D. Blunt, 2025, Immunotherapy Advances, 5(1)

DOI: 10.1093/immadv/ltaf029

Type: article

FcγRIIB (CD32B) antibodies enhance immune responses through activating FcγRs

Alexander P. Simpson, Robert J. Oldham, Kerry L. Cox, Martin C. Taylor, Sonya James, Yury Bogdanov, Martin J. Glennie, Bjorn Frendeus, Mark S. Cragg & Ali Roghanian, 2025, Clinical and Experimental Immunology, 219(1)

DOI: 10.1093/cei/uxaf015

Type: article

FcγRIIB controls antibody-mediated target cell depletion by ITIM-independent mechanisms

Alexander Patrick Simpson, Ali Roghanian, Robert James Oldham, Claude Chan, Christine Penfold, Sonya James, Yury Bogdanov, Christopher Mockridge, Hyung Kim, Tatyana Inzhelevskaya, Stephen Beers & Mark Cragg, 2022, Cell Reports, 40(3)

DOI: 10.1016/j.celrep.2022.111099

Type: article

HIF activation enhances FcγRIIb expression on mononuclear phagocytes impeding tumor targeting antibody immunotherapy

Khiyam Hussain, Rena Liu, Rosanna C G Smith, Kri T J Müller, Mohammadmersad Ghorbani, Sofia Macari, Kirstie L S Cleary, Robert J Oldham, Russell B Foxall, Sonya James, Steven G Booth, Tom Murray, Lekh N Dahal, Chantal E Hargreaves, Robert S Kemp, Jemma Longley, James Douglas, Hannah Markham, Serena J Chee, Richard J Stopforth, Ali Roghanian, Matthew J Carter, Christian H Ottensmeier, Bjorn Frendéus, Ramsey I Cutress, Ruth R French, Martin J Glennie, Jonathan C Strefford, Stephen M Thirdborough, Stephen A Beers & Mark S Cragg, 2022, Journal of Experimental and Clinical Cancer Research, 41(131), 131

DOI: 10.1186/s13046-022-02294-5

Type: article

On-target IgG hexamerisation driven by a C-terminal IgM tail-piece fusion variant confers augmented complement activation

Joshua M. Sopp, Shirley J. Peters, Tania F. Rowley, Robert J. Oldham, Sonya James, Ian Mockridge, Ruth R. French, Alison Turner, Stephen A. Beers, David P. Humphreys & Mark S. Cragg, 2021, Communications Biology, 4(1)

DOI: 10.1038/s42003-021-02513-3

Type: article

Fc-engineering for modulated eﬀector functions—improving antibodies for cancer treatment

Mark Cragg, Robert James Oldham, Emma Louise Teal & Stephen Beers, 2020, Antibodies, 9(4)

DOI: 10.3390/antib9040064

Type: article

The PI3Kδ-selective inhibitor idelalisib minimally interferes with immune effector function mediated by rituximab or obinutuzumab and significantly augments B cell depletion In vivo

Adam Palazzo, Sylvia Herter, Laura Grosmaire, Randy Jones, Christian Frey, Marina Bacac, Pablo Umana, Robert James Oldham, Michael Marshall, Kerry Cox, Anna Turaj, Mark Cragg, Christian Klein, Matthew Carter & Stacey Tannheimer, 2018, Journal of Immunology, 1-10

DOI: 10.4049/jimmunol.1700323

Type: article

Detection of experimental and clinical immune complexes by measuring SHIP-1 recruitment to the inhibitory FcγRIIB

R.J. Stopforth, R.J. Oldham, A.L. Tutt, P. Duriez, H.T.C. Chan, B. Binkowski, C. Zimprich, D. Li, P. Hargreaves, M. Cong, V. Reddy, M. Leandro, G. Cambridge, A. Lux, F. Nimmerjahn & M.S. Cragg, 2018, The Journal of Immunology

DOI: 10.4049/jimmunol.1700832

Type: article

Dr Robert Oldham

Connect with Robert

Publications